271
Participants
Start Date
August 12, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Haukeland Universitetssjukehus, Bergen
Nemours Alfred I. Dupont Hospital for Children, Wilmington
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlino, Milan
Johns Hopkins School of Medicine, Baltimore
Hospital Universitario La Paz, Madrid
Vanderbilt University Medical Center, Nashville
Otto-von-Guericke-University Magdeburg Medical Fakulty, Magdeburg
Cincinnati Children's Hospital, Cincinnati
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison
University of Missouri, Columbia
Children's Hospital Colorado, Aurora
Benioff Children's Hospital Oakland, Oakland
KK Women's and Children's Hospital, Singapore
Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan, Buenos Aires
Murdoch Children's Research Institute, Parkville
Hopital Femme Mere Enfant, Lyon
Hopital Necker-Enfants Malades, Paris
Hopital des Enfants, Toulouse
Hospital Universitario Virgen de la Victoria, Málaga
Bristol Royal Hospital for Children, Bristol
Birmingham Children's Hospital, Birmingham
Queen Elizabeth University Hospital, Glasgow
St. Thomas' Hospital, London
Manchester University Children's Hospital, Manchester
Sheffield Children's Hospital, Sheffield
Stollery Children's Hospital, Edmonton
Children's Hospital - London Health Sciences Center, London
University of Ottawa, Ottawa
University of Montreal, Montreal
Rare Disease Unit Fondazione Policlinico A Gemelli IRCCS, Rome
Oslo Universitetssykehus, Oslo
Vithas Hospital San Jose, Barcelona
QED Therapeutics, Inc., a Bridgebio company
INDUSTRY